Axsome Therapeutics
AXSM
197 hedge funds and large institutions have $1.97B invested in Axsome Therapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 68 increasing their positions, 66 reducing their positions, and 42 closing their positions.
39% more call options, than puts
Call options by funds: $79.2M | Put options by funds: $56.9M
4.1% more ownership
Funds ownership: 69.21% → 73.31% (+4.1%)
3% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 66
10% less funds holding
Funds holding: 219 → 197 (-22)
15% less capital invested
Capital invested by funds: $2.32B → $1.97B (-$351M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
50% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 42
Top Buyers
| 1 |
Millennium Management
New York
|
+$68.3M |
| 2 |
RI
RTW Investments
New York
|
+$52.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.4M |
| 4 |
Holocene Advisors
New York
|
+$34.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$34.1M |
Top Sellers
| 1 |
VA
VR Adviser
New York
|
-$51.7M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$32M |
| 3 |
CC
Cannell & Co
New York
|
-$16.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.8M |
| 5 |
Jane Street
New York
|
-$10.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
HighTower Advisors
Chicago,
Illinois
| – | -$256K | -3,328 | Closed |
|
|
MFS
227
Mirabella Financial Services
London,
United Kingdom
| – | -$255K | -3,311 | Closed |
|
|
AIM
228
Aigen Investment Management
New York
| – | -$235K | -3,046 | Closed |
|
229
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$216K | -2,805 | Closed |
|
|
BCI
230
Brinker Capital Investments
Berwyn,
Pennsylvania
| – | -$207K | -2,681 | Closed |
|
|
SEIA
231
Signature Estate & Investment Advisors
Los Angeles,
California
| – | -$203K | -2,632 | Closed |
|
232
Belvedere Trading
Chicago,
Illinois
| – | -$163K | -2,119 | Closed |
|
|
AWM
233
Ameliora Wealth Management
Zurich,
Switzerland
| – | -$38.6K | -500 | Closed |
|
234
Rockefeller Capital Management
New York
| – | -$27K | -350 | Closed |
|
|
FIA
235
FNY Investment Advisers
New York
| – | -$23K | -308 | Closed |
|
|
NA
236
NewEdge Advisors
New Orleans,
Louisiana
| – | -$7.71K | -100 | Closed |
|
|
RBC
237
Romano Brothers & Co
Evanston,
Illinois
| – | -$1.93K | -25 | Closed |
|
AXSM Hedge Fund Activity: Q1 2023 in Review
197 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2023, worth a combined $1.97B — down 15% from $2.32B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of AXSM and 21 opened new positions — a net loss of 21 holders — while 66 trimmed existing stakes and 68 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $68.3M. The largest seller was VR Adviser, exiting entirely with an estimated $51.7M sold.
- 197 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2023, down from 219 in Q4 2022.
- Funds reported $1.97B of Axsome Therapeutics stock for Q1 2023, down 15% quarter-over-quarter.
- 21 funds opened new Axsome Therapeutics positions in Q1 2023 and 42 closed out, a net change of -21 holders.
- The largest Axsome Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $68.3M added.
- The largest Axsome Therapeutics seller in Q1 2023 was VR Adviser, an estimated $51.7M sold.
Based on aggregated 13F filings for Q1 2023.